Earnings ·
Takeda Pharmaceutical Company Limited reported first-quarter results for the period ended June 30, 2026, showing…
TAKTakeda Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Limited reported first-quarter results for the period ended June 30, 2026, showing revenue of JPY 1,219.9 billion, a 10.2% increase year-over-year driven by foreign exchange impacts. Operating profit rose 9.1% to JPY 201.4 billion, while net profit attributable to owners declined 8.9% to JPY 113.2 billion due to higher income tax expenses and restructuring costs. The company confirmed its full-year management guidance for the fiscal year ending March 31, 2027, projecting a low-single digit decline in Core Revenue growth, a 5% to 8% decline in Core Operating Profit growth, and a mid-teens percent decline in Core EPS growth on a constant exchange rate basis. Takeda operates as a global pharmaceutical company focused on the research, development, manufacturing, and sale of prescription drugs, vaccines, and plasma-derived therapies.